FDA approves Penn’s ‘glowing tumor’ imaging drug to identify ovarian cancer cells FDA approves Penn’s ‘glowing tumor’ imaging drug to identify ovarian cancer cells An injectable diagnostic illuminates cancer tissue that allows for greater precision during surgery was pioneered by surgeons at the University of Pennsylvania.
Changing the identity of cancer cells to eliminate them New findings from a study led by the School of Veterinary Medicine’s Andrés Blanco point a way forward for the treatment of acute myeloid leukemia. (Image: National Cancer Institute) Changing the identity of cancer cells to eliminate them A team led by the School of Veterinary Medicine’s M. Andrés Blanco has uncovered a new target for treating certain blood cancers that works by removing an obstacle to their maturation.
Entering a new phase in cell therapy for glioblastoma Entering a new phase in cell therapy for glioblastoma Donald M. O’Rourke, director of the Glioblastoma Translational Center of Excellence at Penn Medicine, and others are exploring cellular immunotherapies as a potential better option for deadly brain cancer glioblastoma multiforme.
A new class of CAR T cells targets previously untargetable cancer drivers A new class of CAR T cells targets previously untargetable cancer drivers Focusing on neuroblastoma, researchers from the Perelman School of Medicine and Children’s Hospital of Philadelphia have harnessed the immune system to destroy tumors.
Drugs designed for prostate cancer may treat melanoma in men Drugs designed for prostate cancer may treat melanoma in men A new Penn study finds that testosterone contributes to sex differences in melanoma via the activation of the zinc transporter ZIP9.
BRCA1 vs. BRCA2: What to know about these gene mutations and breast cancer Penn In the News Health.com BRCA1 vs. BRCA2: What to know about these gene mutations and breast cancer Payal Shah of the Perelman School of Medicine discussed the gene mutations that can lead to breast, ovarian, and other cancers. Black women face increased risk of triple negative breast cancers Black women face increased risk of triple negative breast cancers An analysis of nearly 200,000 patients highlights the heterogeneity of breast cancer risk factors for women of differing races, ages, and disease subtypes. Penn Medicine and Wistar awarded $11.7 million melanoma research grant Penn Medicine and Wistar awarded $11.7 million melanoma research grant The Specialized Programs of Research Excellence, or SPORE, grant from the National Cancer Institute will fund three new melanoma research projects over five years. Engineering CAR T cells to activate a bodily response to solid tumors Engineering CAR T cells to activate a bodily response to solid tumors A new Penn study shows that CAR T cells expressing RN7SL1, a naturally occurring RNA, can activate the body’s natural immune cells against difficult-to-treat cancers.
Black women face increased risk of triple negative breast cancers Black women face increased risk of triple negative breast cancers An analysis of nearly 200,000 patients highlights the heterogeneity of breast cancer risk factors for women of differing races, ages, and disease subtypes.
Penn Medicine and Wistar awarded $11.7 million melanoma research grant Penn Medicine and Wistar awarded $11.7 million melanoma research grant The Specialized Programs of Research Excellence, or SPORE, grant from the National Cancer Institute will fund three new melanoma research projects over five years.
Engineering CAR T cells to activate a bodily response to solid tumors Engineering CAR T cells to activate a bodily response to solid tumors A new Penn study shows that CAR T cells expressing RN7SL1, a naturally occurring RNA, can activate the body’s natural immune cells against difficult-to-treat cancers.